Price T Rowe Associates Inc Aurinia Pharmaceuticals Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 43,748 shares of AUPH stock, worth $404,669. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,748
Previous 45,707
4.29%
Holding current value
$404,669
Previous $261,000
22.99%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding AUPH
# of Institutions
207Shares Held
58.6MCall Options Held
1.14MPut Options Held
1.51M-
Black Rock Inc. New York, NY9.27MShares$85.8 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY8.2MShares$75.9 Million1.0% of portfolio
-
Tang Capital Management LLC San Diego, CA7.23MShares$66.9 Million4.52% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$36.7 Million2.22% of portfolio
-
State Street Corp Boston, MA2.95MShares$27.2 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.31B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...